Optimistic Buy Rating for Rezolute Driven by Promising Ersodetug Developments and Strong Financial Position

Analyst Yun Zhong of Wedbush reiterated a Buy rating on Rezolute (RZLT – Research Report), retaining the price target of $12.00.

Yun Zhong’s rating is based on the promising developments surrounding Rezolute’s lead candidate, ersodetug, which has shown strong potential in treating congenital hyperinsulinism (cHI) and tumor-induced hyperinsulinism (tHI). The recent interim analysis of the Phase 3 sunRIZE study in cHI demonstrated positive outcomes, with the Data Monitoring Committee recommending the continuation of the study without the need for additional patient enrollment. This suggests a high likelihood of success for the study’s primary endpoint, which focuses on glycemic control.
Moreover, the company’s strengthened financial position, bolstered by a recent public offering, provides a solid runway to mid-2027, supporting the advancement of its clinical programs. The FDA’s Breakthrough Therapy designations for ersodetug in both cHI and tHI further underscore its potential efficacy and facilitate ongoing engagement with the agency. These factors, combined with the planned initiation of the Phase 3 upLIFT study in tHI by mid-2025, contribute to Yun Zhong’s optimistic outlook and Buy rating for Rezolute’s stock.

In another report released on May 6, H.C. Wainwright also reiterated a Buy rating on the stock with a $14.00 price target.